Document is current

Article History

Received: 25 March 2021

Accepted: 3 August 2021

First Online: 8 September 2021

Declarations

:

: This study was carried out in accordance with the Declaration of Helsinki. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to Corrona, LLC prior to the initiation of any study procedures.

: All patients in the registry were required to provide written informed consent and authorization prior to participating.

: PJM has received research grants and has served as a consultant or has been a speaker for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. SS, MG, and DHC are employees of and have received stocks/stock options from Amgen. ML is an employee of Corrona, LLC that has been supported through contracted subscriptions in the last 2 years from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB Pharma. BS is an employee of Axio Research, LLC. SR was an employee of Corrona, LLC at the time of the study and writing of this manuscript.